Morphotek Inc. recently entered a Sponsored Research Agreement (SRA) along with Fox Chase Cancer Center (FCCC) that will lead to the expansion of its efforts to research how efficient immune-based therapies are in relation to the immunosuppressive effects that are caused by tumor shed antigens. Read More »
Antibody product is a potential treatment for Huntington's Disease. Read More »
DelMar Pharmaceuticals Inc. recently presented new data in a research poster called, “Activity of dianhydrogalactitol (VAL-083) in ovarian tumor models, sensitive or resistant to cisplatin” at the 11th Biennial Ovarian Cancer Research Symposium. Read More »
Gate Pharmaceuticals Inc. today announced that its subsidiary, Jade Therapeutics, has received a second year of funding from the U.S. Army Medical Research and Material Command (USAMRMC) for a total of $448,185 to develop proprietary thiolated hyaluronic acid for use as an ocular bandage film. Read More »
DelMar Pharmaceuticals Inc. recently partnered with Accurexa Inc. for the development of a novel formulation that will treat brain cancer and other solid tumors. Read More »
Valeant Pharmaceuticals International recently acquired the necessary lender approval for a credit facility amendment. Read More »
Collegium Pharmaceuticals Inc. announced that an independent review of Xtampza ER will be published in The Journal of the American Medical Association (JAMA). Read More »
ProclaRx recently appointed Doug Martin as its new COO, assigning him strategic planning, compliance and coordination of R&D duties. Read More »
Foam Pharmaceuticals Ltd., a clinical stage specialty pharmaceutical company dedicated to the development and commercialization of topical foams to fill unmet dermatology needs, will be releasing the results of its Phase 2 FMX103 clinical trial on Sept. 12. Read More »
Antibiotic agent treats severe drug-resistant bacterial skin and skin structure infections. Read More »
The reason for the recall are two complaints from customers in the United Kingdom and Portugal that involve the detachment of needles from the syringe with SWFI, or Sterile Water for Injection. Read More »
Achillion Pharmaceuticals Inc. today announced that the interim results of its ongoing phase 2a study, conducted by Alios BioPharma, part of the Janssen Pharmaceutical Companies, will be presented at the European Association for the Study of the Liver (EASL) Special Conference. Read More »
Phase III study shows up to 40 percent reduction in seizures in study participants. Read More »
Naldemedine found effective in treating OIC in a year-long Phase III study. Read More »
CVS Health has announced the launch of Project Health, its free health services campaign that is held on an annual basis. Read More »
Amgen has announced that the data from studies involving romosozumab and Prolia will be presented at the Annual Meeting of American Society for Bone and Mineral Research (ASBMR) on Sept. 16-19 in Atlanta, Georgia. Read More »
Imprimis Pharmaceuticals this week announced that it has launched its new patient assistance program, Imprimis Cares Access Network (ICAN). Read More »
HSRx Biopharmaceutical has announced that HSRx 431, the company’s broad-spectrum antiviral drug candidate that is administered orally, has shown that it is effective against the Zika virus. Read More »
Sangamo BioSciences Inc. recently announced that SB-FIX has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA). Read More »
Avara Pharmaceuticals Services Inc. recently announced that it has come to terms on an agreement for the acquisition of a manufacturing facility from AstraZeneca located in Avlon, Avonmouth, England. Read More »
Alerts Sign-up
